• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Research Brief on 3,4-Difluoro-benzenebutanoic Acid (CAS: 136295-00-6): Recent Advances and Applications

3,4-Difluoro-benzenebutanoic acid (CAS: 136295-00-6) is a fluorinated aromatic carboxylic acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the design of enzyme inhibitors and receptor modulators. This research brief aims to provide an overview of the latest advancements related to this compound, focusing on its synthetic utility, biological activities, and emerging therapeutic applications.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the use of 3,4-Difluoro-benzenebutanoic acid as a building block for the development of novel nonsteroidal anti-inflammatory drugs (NSAIDs). The researchers demonstrated that the incorporation of fluorine atoms at the 3 and 4 positions of the phenyl ring significantly enhanced the metabolic stability and bioavailability of the resulting compounds. The study utilized a combination of computational modeling and in vitro assays to optimize the pharmacokinetic properties of the derivatives, achieving a 2.5-fold increase in plasma half-life compared to non-fluorinated analogs.

In the field of oncology, 3,4-Difluoro-benzenebutanoic acid has been investigated as a precursor for the synthesis of small-molecule inhibitors targeting protein kinases involved in cancer progression. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported the development of a series of potent EGFR inhibitors derived from this compound, showing IC50 values in the low nanomolar range against resistant cancer cell lines. The fluorinated aromatic core was found to play a critical role in maintaining the planar conformation necessary for optimal binding to the ATP pocket of the kinase domain.

Recent advances in synthetic methodology have also expanded the utility of 3,4-Difluoro-benzenebutanoic acid in medicinal chemistry. A breakthrough publication in Organic Letters (2023) described a novel palladium-catalyzed cross-coupling reaction that enables direct functionalization of the butanoic acid side chain, significantly expanding the structural diversity accessible from this scaffold. This methodological innovation has opened new avenues for the rapid generation of compound libraries for high-throughput screening campaigns.

The compound's potential in central nervous system (CNS) drug development was highlighted in a 2024 Nature Communications paper, where researchers demonstrated its incorporation into GABA receptor modulators with improved blood-brain barrier penetration. The fluorinated aromatic system was shown to reduce P-glycoprotein-mediated efflux, addressing a common challenge in CNS drug development. These findings suggest promising applications for 3,4-Difluoro-benzenebutanoic acid derivatives in the treatment of neurological disorders.

From a safety and toxicology perspective, recent preclinical studies have provided valuable data on the metabolic fate of 3,4-Difluoro-benzenebutanoic acid derivatives. A comprehensive ADMET study published in Chemical Research in Toxicology (2023) revealed that the fluorinated compounds exhibit favorable metabolic profiles with reduced formation of reactive metabolites compared to their non-fluorinated counterparts. This characteristic makes them particularly attractive for long-term therapeutic applications where drug safety is paramount.

Looking forward, the unique physicochemical properties imparted by the difluorinated aromatic system continue to drive innovation in multiple therapeutic areas. Ongoing research is exploring the application of 3,4-Difluoro-benzenebutanoic acid derivatives in targeted protein degradation (PROTACs), antibody-drug conjugates (ADCs), and as imaging probes for positron emission tomography (PET). The compound's versatility and the growing understanding of its structure-activity relationships position it as a valuable tool in modern drug discovery pipelines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)